6 research outputs found
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo
Infectious diseases
continue to pose a substantial burden on global
populations, requiring innovative broad-spectrum prophylactic and
treatment alternatives. Here, we have designed modular synthetic polymer
nanoparticles that mimic functional components of host cell membranes,
yielding multivalent nanomimics that act by directly binding to varied
pathogens. Nanomimic blood circulation time was prolonged by reformulating
polymer–lipid hybrids. Femtomolar concentrations of the polymer
nanomimics were sufficient to inhibit herpes simplex virus type 2
(HSV-2) entry into epithelial cells, while higher doses were needed
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Given their observed virustatic mode of action, the nanomimics were
also tested with malaria parasite blood-stage merozoites, which lose
their invasive capacity after a few minutes. Efficient inhibition
of merozoite invasion of red blood cells was demonstrated both in vitro and in vivo using a preclinical
rodent malaria model. We envision these nanomimics forming an adaptable
platform for developing pathogen entry inhibitors and as immunomodulators,
wherein nanomimic-inhibited pathogens can be secondarily targeted
to sites of immune recognition
